Cancer Immunotherapy Market (By Product Type: Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immunomodulators; By Application: Breast Cancer: Lung Cancer, Multiple Myeloma, Colorectal Cancer, Head & Neck Cancer, Prostate Cancer, Melanoma, Others; By End-user: Hospitals, Clinics & Others) – Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

Table Of Content:

CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
   1.1.1. Definition of Cancer Immunotherapy
   1.1.2. Market Segmentation
   1.1.3. List of Abbreviations
1.2. Summary
   1.2.1. Market Snapshot
   1.2.2. Cancer Immunotherapy Market By Product Type
     1.2.2.1. Global Cancer Immunotherapy Market Revenue and Growth Rate Comparison By Product Type (2015-2026)
     1.2.2.2. Global Cancer Immunotherapy Market Revenue Share By Product Type in 2018
     1.2.2.3. Monoclonal Antibodies
     1.2.2.4. Vaccines
     1.2.2.5. Checkpoint Inhibitors
     1.2.2.6. Cell Therapies
     1.2.2.7. Immunomodulators
   1.2.3. Cancer Immunotherapy Market By Application
     1.2.3.1. Global Cancer Immunotherapy Market Revenue and Growth Rate Comparison By Application (2015-2026)
       1.2.3.1.1. Breast Cancer
       1.2.3.1.2. Lung Cancer
       1.2.3.1.3. Multiple Myeloma
       1.2.3.1.4. Colorectal Cancer
       1.2.3.1.5. Head & Neck Cancer
       1.2.3.1.6. Prostate Cancer
       1.2.3.1.7. Melanoma
       1.2.3.1.8. Others
   1.2.4. Cancer Immunotherapy Market By End-user
     1.2.4.1. Global Cancer Immunotherapy Market Revenue and Growth Rate Comparison By End-user (2015-2026)
     1.2.4.2. Hospitals
     1.2.4.3. Clinics & Others
   1.2.5. Cancer Immunotherapy Market By Geography
     1.2.5.1. Global Cancer Immunotherapy Market Revenue and Growth Rate Comparison By Geography (2015-2026)
     1.2.5.2. North America Cancer Immunotherapy Market Revenue and Growth Rate(2015-2026)
     1.2.5.3. Europe Cancer Immunotherapy Market Revenue and Growth Rate(2015-2026)
     1.2.5.4. Asia-Pacific Cancer Immunotherapy Market Revenue and Growth Rate(2015-2026)
     1.2.5.5. Latin America Cancer Immunotherapy Market Revenue and Growth Rate(2015-2026)
     1.2.5.6. Middle East and Africa (MEA) Cancer Immunotherapy Market Revenue and Growth Rate(2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
   2.4.1. Bargaining Power of Suppliers
   2.4.2. Bargaining Power of Buyers
   2.4.3. Threat of Substitute
   2.4.4. Threat of New Entrants
   2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
   2.6.1. Raw Material and Suppliers
   2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2018
   2.8.1. Player Positioning Analysis
   2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Cancer Immunotherapy Major Manufacturers in 2018
3.2. Manufacturing Plants Distribution of Global Cancer Immunotherapy Major Manufacturers in 2018
3.3. R&D Status and Technology Source of Global Cancer Immunotherapy Major Manufacturers in 2018
3.4. Raw Materials Sources Analysis of Global Cancer Immunotherapy Major Manufacturers in 2018

CHAPTER 4. CANCER IMMUNOTHERAPY MARKET BY PRODUCT TYPE
4.1. Global Cancer Immunotherapy RevenueBy Product Type
4.2. Monoclonal Antibodies
   4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
   4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Vaccines
   4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
   4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Checkpoint Inhibitors
   4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
   4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Cell Therapies
   4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
   4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Immunomodulators
   4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
   4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. CANCER IMMUNOTHERAPY MARKET BY APPLICATION
5.1. Global Cancer Immunotherapy RevenueBy Application
5.2. Breast Cancer
   5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
   5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Lung Cancer
   5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
   5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Multiple Myeloma
   5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
   5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Colorectal Cancer
   5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
   5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Head & Neck Cancer
   5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
   5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.7. Prostate Cancer
   5.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
   5.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.8. Melanoma
   5.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
   5.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.9. Others
   5.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
   5.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. CANCER IMMUNOTHERAPY MARKET BY END-USER
6.1. Global Cancer Immunotherapy Revenue By End-user
6.2. Hospitals
   6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
   6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Clinics & Others
   6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
   6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY COUNTRY
7.1. North America Cancer Immunotherapy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Cancer Immunotherapy Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
   7.3.1. U.S.Cancer Immunotherapy Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   7.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   7.3.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
7.4. Canada
   7.4.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   7.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   7.4.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE CANCER IMMUNOTHERAPY MARKET BY COUNTRY
8.1. Europe Cancer Immunotherapy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Cancer Immunotherapy Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
   8.3.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   8.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   8.3.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.4. Germany
   8.4.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   8.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   8.4.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.5. France
   8.5.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   8.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   8.5.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.6. Spain
   8.6.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   8.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   8.6.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.7. Rest of Europe
   8.7.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   8.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   8.7.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFICCANCER IMMUNOTHERAPY MARKET BY COUNTRY
9.1. Asia-Pacific Cancer Immunotherapy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-PacificCancer Immunotherapy Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
   9.3.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   9.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   9.3.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.4. Japan
   9.4.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   9.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   9.4.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.5. India
   9.5.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   9.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   9.5.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.6. Australia
   9.6.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   9.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   9.6.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.7. South Korea
   9.7.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   9.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   9.7.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
   9.8.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   9.8.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   9.8.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET BY COUNTRY
10.1. Latin America Cancer Immunotherapy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Cancer Immunotherapy Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
   10.3.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   10.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   10.3.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.4. Mexico
   10.4.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   10.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   10.4.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.5. Rest of Latin America
   10.5.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   10.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   10.5.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET BY COUNTRY
11.1. Middle East & Africa Cancer Immunotherapy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East & Africa Cancer Immunotherapy Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. GCC
   11.3.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   11.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   11.3.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.4. South Africa
   11.4.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   11.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   11.4.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.5. Rest of Middle East & Africa
   11.5.1. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
   11.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
   11.5.3. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 12. COMPANY PROFILE
12.1. Novartis AG
   12.1.1. Company Snapshot
   12.1.2. Overview
   12.1.3. Financial Overview
   12.1.4. Type Portfolio
   12.1.5. Key Developments
   12.1.6. Strategies
12.2. Bayer AG
   12.2.1. Company Snapshot
   12.2.2. Overview
   12.2.3. Financial Overview
   12.2.4. Type Portfolio
   12.2.5. Key Developments
   12.2.6. Strategies
12.3. Amgen Inc.
   12.3.1. Company Snapshot
   12.3.2. Overview
   12.3.3. Financial Overview
   12.3.4. Type Portfolio
   12.3.5. Key Developments
   12.3.6. Strategies
12.4. Astrazeneca
   12.4.1. Company Snapshot
   12.4.2. Overview
   12.4.3. Financial Overview
   12.4.4. Type Portfolio
   12.4.5. Key Developments
   12.4.6. Strategies
12.5. Bristol-Myers Squibb
   12.5.1. Company Snapshot
   12.5.2. Overview
   12.5.3. Financial Overview
   12.5.4. Type Portfolio
   12.5.5. Key Developments
   12.5.6. Strategies
12.6. ELI Lilly and Company
   12.6.1. Company Snapshot
   12.6.2. Overview
   12.6.3. Financial Overview
   12.6.4. Type Portfolio
   12.6.5. Key Developments
   12.6.6. Strategies
12.7. Janssen Global Services, LLC
   12.7.1. Company Snapshot
   12.7.2. Overview
   12.7.3. Financial Overview
   12.7.4. Type Portfolio
   12.7.5. Key Developments
   12.7.6. Strategies
12.8. Merck
   12.8.1. Company Snapshot
   12.8.2. Overview
   12.8.3. Financial Overview
   12.8.4. Type Portfolio
   12.8.5. Key Developments
   12.8.6. Strategies
12.9. Pfizer
   12.9.1. Company Snapshot
   12.9.2. Overview
   12.9.3. Financial Overview
   12.9.4. Type Portfolio
   12.9.5. Key Developments
   12.9.6. Strategies
12.10. F. Hoffmann-La Roche Ltd
   12.10.1. Company Snapshot
   12.10.2. Overview
   12.10.3. Financial Overview
   12.10.4. Type Portfolio
   12.10.5. Key Developments
   12.10.6. Strategies
12.11. Others
   12.11.1. Company Snapshot
   12.11.2. Overview
   12.11.3. Financial Overview
   12.11.4. Type Portfolio
   12.11.5. Key Developments
   12.11.6. Strategies

CHAPTER 13. RESEARCH APPROACH
13.1. Research Methodology
   13.1.1. Initial Data Search
   13.1.2. Secondary Research
   13.1.3. Primary Research
13.2. Assumptions and Scope